Pieris Pharmaceuticals Presents Clinical Data for its Hepcidin Antagonist Program, Prs-080, at the 2015 American Society of Hematology (Ash) Annual Meeting

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® bio therapeutic technologies, announced today that it will present detailed data today summarizing the results from a Phase I clinical study in healthy male volunteers with its PRS-080 Anticalin hepcidin antagonist at the 57th Annual Meeting of the American Society of Hematology (ASH) taking place in Orlando, FL.Read more...

Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia

Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today the completion of enrollment of healthy subjects in a blinded, placebo-controlled Phase I clinical trial for the Company's PRS-080 program, a hepcidin antagonist to treat anemia. This study was conducted at a single site in Germany.Read more...

Pieris Initiates Phase I Clinical Trial for Anticalin® to Treat Anemia

Freising, Germany, December 11, 2014 -- Pieris AG announced today the initiation of a Phase I clinical trial with PRS-080, an anti-hepcidin Anticalin® therapeutic protein designed to treat anemia. The trial is a placebo-controlled, single ascending dose evaluation of the compound’s safety and tolerability in healthy volunteers. Conducted in Germany, the trial is underway and patients from the first cohort have been dosed.
Read more...

In Dutch from partner UMC St. Radboud: Zes miljoen voor nieuw medicijn tegen bloedarmoede

Hepcidinanalysis.com, een BV van het UMC St Radboud, heeft met negen partners een Europese subsidie binnengehaald van zes miljoen euro. Samen gaan ze nieuwe stoffen testen (anticalines), die bloedarmoede bestrijden door beïnvloeding van de ijzerstofwisseling. Nieuwe medicijnen zijn zeer welkom voor patiënten met bloedarmoede vanwege nierziekten, auto-immuunziekten, reuma of een andere chronische ziekte.Read more...

EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia

-- Consortium Will Receive Six Million Euros from Seventh Framework Programme --

Freising, Germany, October 19, 2011—The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining and completing initial clinical development of a novel Anticalin® therapeutic. The project will be funded in large part by the European Commission Seventh Framework Programme (FP7-Health.2011.1.4.3; Grant Agreement number 278408). Anticalins are novel, next generation therapeutic proteins designed to bind and antagonize a wide spectrum of ligands. As funded by the grant, the Consortium will develop, manufacture and clinically test an Anticalin specific for hepcidin. Hepcidin, a small peptide circulating in human blood, is considered to be a key regulator of iron homeostasis and, therefore, an important target for the treatment of multiple types of anemia.
Read more...